Literature DB >> 27939447

Differential response and withdrawal profile of glucocorticoid-treated human trabecular meshwork cells.

Guorong Li1, Gang Cui2, W Michael Dismuke1, Iris Navarro1, Kristin Perkumas1, David F Woodward3, W Daniel Stamer4.   

Abstract

The goal of the study was to examine secreted protein response and withdrawal profiles from cultured human trabecular meshwork (HTM) cells following short- and long-term glucocorticoid treatment. Primary cultures of five human HTM cell strains isolated from 5 different individual donor eyes were tested. Confluent HTM cells were differentiated in culture media containing 1% FBS for at least one week, and then treated with Dexamethasone (Dex, 100 nM) 3 times/week for 1 or 4 weeks. Cell culture supernatants were collected 3 times per week for 8 weeks. Secretion profiles of myocilin (MYOC), matrix metalloproteinase-2 (MMP2) and fibronectin (FN) were determined by Western blot analysis and MMP2 activity by zymography. Dex treatment reduced MMP2 expression and activity, returning to normal levels shortly after Dex withdrawal in 5 HTM cell strains. All five cell strains significantly upregulated MYOC in response to Dex treatment by an average of 17-fold, but recovery to basal levels after Dex withdrawal took vastly different periods of time depending on cell strain and treatment duration. Dex treatment significantly increased FN secretion in all strains but one, which decreased FN secretion in the presence of Dex. Interestingly, secretion of FN and MYOC negatively correlated during a 4 week recovery period following 4 weeks of Dex treatment. Taken together, the time course and magnitude of response and recovery for three different secreted, extracellular matrix-associated proteins varied greatly between HTM cell strains, which may underlie susceptibility to glucocorticoid-induced ocular hypertension.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Conventional outflow; Dexamethasone; Extracellular matrix; Glaucoma; Ocular hypertension

Mesh:

Substances:

Year:  2016        PMID: 27939447      PMCID: PMC5359060          DOI: 10.1016/j.exer.2016.12.002

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  60 in total

1.  Use of gel zymography to examine matrix metalloproteinase (gelatinase) expression in brain tissue or in primary glial cultures.

Authors:  Harald Frankowski; Yu-Huan Gu; Ji Hoe Heo; Richard Milner; Gregory J Del Zoppo
Journal:  Methods Mol Biol       Date:  2012

2.  Recombinant TIGR/MYOC increases outflow resistance in the human anterior segment.

Authors:  M P Fautsch; C K Bahler; D J Jewison; D H Johnson
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-12       Impact factor: 4.799

3.  CORTICOSTEROIDS AND INTRAOCULAR PRESSURE.

Authors:  B BECKER; D W MILLS
Journal:  Arch Ophthalmol       Date:  1963-10

Review 4.  Extracellular matrix structure.

Authors:  Achilleas D Theocharis; Spyros S Skandalis; Chrysostomi Gialeli; Nikos K Karamanos
Journal:  Adv Drug Deliv Rev       Date:  2015-11-10       Impact factor: 15.470

5.  NFATc1 activity regulates the expression of myocilin induced by dexamethasone.

Authors:  Jennifer A Faralli; Ross W Clark; Mark S Filla; Donna M Peters
Journal:  Exp Eye Res       Date:  2014-11-18       Impact factor: 3.467

6.  Morphologic changes in the outflow pathways of bovine eyes treated with corticosteroids.

Authors:  Ozan-Yüksel Tektas; Christian Manfred Hammer; John Danias; Oscar Candia; Rosana Gerometta; Steven M Podos; Elke Lütjen-Drecoll
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-03-17       Impact factor: 4.799

7.  Ultrastructural changes in the trabecular meshwork of human eyes treated with corticosteroids.

Authors:  D Johnson; J Gottanka; C Flügel; F Hoffmann; R Futa; E Lütjen-Drecoll
Journal:  Arch Ophthalmol       Date:  1997-03

8.  Autophagic dysregulation in glaucomatous trabecular meshwork cells.

Authors:  Kristine Porter; Joshua Hirt; W Daniel Stamer; Paloma B Liton
Journal:  Biochim Biophys Acta       Date:  2014-12-04

9.  Accurate Imputation-Based Screening of Gln368Ter Myocilin Variant in Primary Open-Angle Glaucoma.

Authors:  Puya Gharahkhani; Kathryn P Burdon; Alex W Hewitt; Matthew H Law; Emmanuelle Souzeau; Grant W Montgomery; Graham Radford-Smith; David A Mackey; Jamie E Craig; Stuart MacGregor
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-08       Impact factor: 4.799

Review 10.  MMPs in the trabecular meshwork: promising targets for future glaucoma therapies?

Authors:  Lies De Groef; Inge Van Hove; Eline Dekeyster; Ingeborg Stalmans; Lieve Moons
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-11-21       Impact factor: 4.799

View more
  4 in total

1.  Pentablock copolymer dexamethasone nanoformulations elevate MYOC: in vitro liberation, activity and safety in human trabecular meshwork cells.

Authors:  Vibhuti Agrahari; Guorong Li; Vivek Agrahari; Iris Navarro; Kristin Perkumas; Abhirup Mandal; W Daniel Stamer; Ashim K Mitra
Journal:  Nanomedicine (Lond)       Date:  2017-07-31       Impact factor: 5.307

2.  Expression profile analysis to identify potential gene changes induced by dexamethasone in the trabecular meshwork.

Authors:  Miao Wei; Lu-Ming Chen; Ze-Yu Huang; Guo-Wei Zhang; Huai-Jin Guan; Min Ji
Journal:  Int J Ophthalmol       Date:  2022-08-18       Impact factor: 1.645

3.  Increased Complement-Associated Inflammation in Cytomegalovirus-Positive Hypertensive Anterior Uveitis Patients Based on the Aqueous Humor Proteomics Analysis.

Authors:  Jin A Choi; Hyun-Hee Ju; Jiyoung Lee; Ju-Eun Kim; Soon-Young Paik; Nikolai P Skiba; Ponugoti Vasantha Rao
Journal:  J Clin Med       Date:  2022-04-22       Impact factor: 4.964

Review 4.  Physiological function of myocilin and its role in the pathogenesis of glaucoma in the trabecular meshwork (Review).

Authors:  Hongwei Wang; Mingzhe Li; Zhenzhen Zhang; Haifeng Xue; Xing Chen; Yong Ji
Journal:  Int J Mol Med       Date:  2018-11-20       Impact factor: 4.101

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.